n.a. (NEOP)

0.00
OTC BB
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange OTC BB
Shares Outstanding 3.00M
Div & Yield N.A. (N.A)
Neoprobe Corporation Becomes Navidea Biopharmaceuticals

Neoprobe Corporation Becomes Navidea Biopharmaceuticals

Neoprobe Corporation (NEOP) today announced that it has completed its corporate name change to Navidea Biopharmaceuticals, Inc.

Neoprobe Secures $10 Million In Debt Financing From Hercules

Neoprobe Secures $10 Million In Debt Financing From Hercules

Neoprobe Corporation (NYSE Amex: NEOP) today announced that Hercules Technology II, L.

David Bupp To Retire From Neoprobe Board Of Directors

David Bupp To Retire From Neoprobe Board Of Directors

(NYSE Amex: NEOP) Neoprobe’s Board of Directors today announced that former President and Chief Executive Officer, David Bupp, will retire as a Director of Neoprobe Corporation effective January 4, 2012.

Neoprobe Licenses AstraZeneca Imaging Agent For Amyloid Detection To Aid Diagnosis Of Alzheimer’s Disease

Neoprobe Licenses AstraZeneca Imaging Agent For Amyloid Detection To Aid Diagnosis Of Alzheimer’s Disease

Neoprobe Corporation (NYSE Amex: NEOP) today announced that it has in-licensed the worldwide exclusive rights from AstraZeneca to the late-stage radiopharmaceutical imaging candidate, AZD4694, for aiding the diagnosis...

Neoprobe Corporation To Change Company Name To Navidea Biopharmaceuticals

Neoprobe Corporation To Change Company Name To Navidea Biopharmaceuticals

Neoprobe Corporation (NYSE Amex: NEOP), today announced that it will change its name to Navidea Biopharmaceuticals, Inc.

Neoprobe To Present At The Oppenheimer & Co. 22nd Annual Healthcare Conference

Neoprobe To Present At The Oppenheimer & Co. 22nd Annual Healthcare Conference

Neoprobe Corporation (NYSE Amex: NEOP) today announced that Dr. Mark Pykett, President and Chief Executive Officer, will participate at the Oppenheimer & Co.

Neoprobe Corporation To Participate At Upcoming Investor Conferences

Neoprobe Corporation To Participate At Upcoming Investor Conferences

Neoprobe Corporation (NYSE Amex: NEOP) today announced that Dr. Mark Pykett, Neoprobe’s President and Chief Executive Officer will be participating in the following investor conferences over the coming weeks: ...

Neoprobe To Present At The Lazard Capital Markets 8th Annual Healthcare Conference

Neoprobe To Present At The Lazard Capital Markets 8th Annual Healthcare Conference

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Neoprobe Announces Third Quarter 2011 Results

Neoprobe Announces Third Quarter 2011 Results

Neoprobe Corporation (NYSE Amex: NEOP), a developer of innovative precision diagnostics products, today announced consolidated results for the third quarter of 2011 and for the nine-month period ended September 30,...

Neoprobe 3rd Quarter 2011 Earnings And Business Update Conference Call Invitation

Neoprobe 3rd Quarter 2011 Earnings And Business Update Conference Call Invitation

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the third quarter of 2011 on Wednesday,...

Biotech Stock Mailbag: Idenix vs. Pharmasset?

Biotech Stock Mailbag: Idenix vs. Pharmasset?

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

5 Stocks Under $10 With Big Upside Potential

5 Stocks Under $10 With Big Upside Potential

These under-$10 stocks look poised to trade higher from current levels.

Biotech Stock Live Chat

Biotech Stock Live Chat

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

Neoprobe Stock Gaps Up On Today's Open (NEOP)

Neoprobe Stock Gaps Up On Today's Open (NEOP)

Shares of Neoprobe Corporation (AMEX:NEOP) were gapping up Thursday morning with an open price 17.9% higher than Wednesday's closing price. The stock closed at $2.63 yesterday and opened today's trading at $3.10.

Neoprobe Proves A Short Seller Wrong

Neoprobe Proves A Short Seller Wrong

FDA acceptance of Neoprobe's application for a lymph-node mapping agent is a defeat for a hedge fund manager who waged a campaign to stop the review.

Neoprobe Receives FDA Acceptance Of Lymphoseek® (tilmanocept) New Drug Application

Neoprobe Receives FDA Acceptance Of Lymphoseek® (tilmanocept) New Drug Application

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its New Drug Application (NDA) for Lymphoseek ® (tilmanocept) has been...

Neoprobe To Present At Credit Suisse 2nd Annual Small & Mid Cap Conference

Neoprobe To Present At Credit Suisse 2nd Annual Small & Mid Cap Conference

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Neoprobe To Present At JMP Securities Healthcare Conference

Neoprobe To Present At JMP Securities Healthcare Conference

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Brent Larson, Neoprobe’s Senior Vice President and Chief Financial ...

Neoprobe To Present At Rodman & Renshaw Annual Global Investment Conference

Neoprobe To Present At Rodman & Renshaw Annual Global Investment Conference

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Neoprobe Stock Gaps Up On Today's Open (NEOP)

Neoprobe Stock Gaps Up On Today's Open (NEOP)

Shares of Neoprobe Corporation (AMEX:NEOP) were gapping up Thursday morning with an open price 10.7% higher than Wednesday's closing price. The stock closed at $2.98 yesterday and opened today's trading at $3.30.

Neoprobe Receives Positive Scientific Advice From European Medicines Agency (EMA) For RIGScan CR

Neoprobe Receives Positive Scientific Advice From European Medicines Agency (EMA) For RIGScan CR

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative diagnostic products, today announced that it received positive scientific advice late last week from the European Medicines Agency (EMA) on...

Neoprobe To Present At Stifel Nicolaus Healthcare Conference 2011

Neoprobe To Present At Stifel Nicolaus Healthcare Conference 2011

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Neoprobe Completes Sale Of Gamma Detection Device Business To Devicor Medical Products

Neoprobe Completes Sale Of Gamma Detection Device Business To Devicor Medical Products

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced today that it completed the previously announced sale of its neoprobe ® GDS line...

Neoprobe Elects Gordon Troup Chairman Of The Board

Neoprobe Elects Gordon Troup Chairman Of The Board

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Gordon A.

Neoprobe Announces 2011 Annual Meeting Results

Neoprobe Announces 2011 Annual Meeting Results

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced the results of voting at its 2011 Annual Meeting of Stockholders (the Annual...

Biotech Stock Mailbag: Cyclacel Pharma

Biotech Stock Mailbag: Cyclacel Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Neoprobe Stock Gaps Up On Today's Open (NEOP)

Neoprobe Stock Gaps Up On Today's Open (NEOP)

Shares of Neoprobe Corporation (AMEX:NEOP) were gapping up Thursday morning with an open price 13.7% higher than Wednesday's closing price. The stock closed at $2.27 yesterday and opened today's trading at $2.58.

Neoprobe Submits New Drug Application For Lymphoseek

Neoprobe Submits New Drug Application For Lymphoseek

Neoprobe Corporation (AMEX: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it has submitted a New Drug Application (NDA) for Lymphoseek ® (tilmanocept) to...

Neoprobe Stock Soars (NEOP)

Neoprobe Stock Soars (NEOP)

Shares of Neoprobe Corporation (AMEX:NEOP) have taken a tremendous swing upward. The stock is trading at $2.65 as of 3:56 p.m. ET, 35.9% above Monday's closing price of $1.95. Volume is at 1.1 million, 0.8 times the daily average of 1.5 million.

Amag: Hedge Fund Makes Takeover Bid

Amag: Hedge Fund Makes Takeover Bid

MSMB Capital proposes an $18-a-share bid for Amag Pharma to stop a questionable merger with Allos Therapeutics.